Table 1 Patients characteristics and anti-SARS-CoV-2 seroconversion rate.
No (%) | ||||
|---|---|---|---|---|
Characteristic | Patients (n = 189) | Seropositive (n = 162) | Seronegative (n = 27) | p-value |
Age, median (range) years | 62.6 (21-87) | 62.7 (21-85) | 59.8 (33-87) | 0.74 |
Gender | 1.00 | |||
Male | 119 (63.0) | 102 (85.7) | 17 (14.3) | |
Female | 70 (37.0) | 60 (85.7) | 10 (14.3) | |
Presence of comorbidities (≥1) | 87 (46.0) | 73 (83.9) | 14 (16.1) | 0.51 |
Cancer diagnosis | 0.26 | |||
Lymphoid malignancies | 92 (48.7) | 75 (81.5) | 17 (18.5) | |
Myeloid neoplasms | 53 (28.0) | 48 (90.6) | 5 (9.4) | |
Plasma cell disorders | 44 (23.3) | 39 (88.6) | 5 (11.4) | |
Cancer status during SARS-CoV-2 infection | 0.01 | |||
Watch and wait | 37 (19.6) | 35 (94.6) | 2 (5.4) | |
Stable/Progressive disease | 33 (17.5) | 23 (69.7) | 10 (30.3) | |
Complete/Partial response | 117 (61.9) | 102 (87.2) | 15 (12.8) | |
Active anti-cancer treatment during SARS-CoV-2 infection | 71 (37.6) | 57 (80.3) | 14 (19.7) | 0.11 |
Chemotherapy-based treatment during SARS-CoV-2 infection | 27 (38.0) | 20 (74.1) | 7 (25.9) | 0.30 |
Chemotherapy-free treatment during SARS-CoV-2 infection | 44 (62.0) | 37 (84.1) | 7 (15.9) | |
Severe/ Critical COVID-19 | 45 (23.8) | 42 (93.3) | 3 (6.7) | 0.11 |
Time from first SARS-CoV-2-positive test to antibody testing ≤ 6 months | 152 (80.4) | 131 (86.2) | 21 (13.8) | 0.71 |
Time from first SARS-CoV-2-positive test to antibody testing > 6 months | 37 (19.6) | 31 (83.8) | 6 (16.2) | |
